The Current State of Screening and Decolonization for the Prevention of Staphylococcus aureus Surgical Site Infection After Total Hip and Knee Arthroplasty.
The most common pathogens in surgical site infections after total hip and knee arthroplasty are methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and coagulase-negative staphylococci. Patients colonized with MSSA or MRSA have an increased risk for a staphylococcal infection at the site of a total hip or knee arthroplasty. Most colonized individuals who develop a staphylococcal infection at the site of a total hip or total knee arthroplasty have molecularly identical S. aureus isolates in their nares and wounds. Screening and nasal decolonization of S. aureus can potentially reduce the rates of staphylococcal surgical site infection after total hip and total knee arthroplasty.
Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 9th Floor, Box 1188, New York, NY 10029. E-mail address for M.C. Weiser: mitchell.weiser@mountsinai.org. E-mail address for C.S. Moucha: calin.moucha@mountsinai.org.
Mitchell C
MC
Weiser
Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 9th Floor, Box 1188, New York, NY 10029. E-mail address for M.C. Weiser: mitchell.weiser@mountsinai.org. E-mail address for C.S. Moucha: calin.moucha@mountsinai.org.
Calin S
CS
Moucha
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000379:methods; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects / Q000379:methods*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects / Q000379:methods*; D004203:Disinfection / Q000379:methods; D042241:Early Diagnosis; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D011300:Preoperative Care / Q000379:methods; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus; D013530:Surgical Wound Infection / Q000517:prevention & control*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents